サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159368

腎臓がんの世界市場（2022年～2028年）

Kidney Cancer Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
腎臓がんの世界市場（2022年～2028年）
出版日: 2022年10月18日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎臓がんの市場規模は、予測期間中に6.2%の大幅なCAGRで成長すると予測されています。市場の成長を後押しする主な要因には、身体活動の低下、過度な喫煙・飲酒などが挙げられます。

当レポートでは、世界の腎臓がん市場を調査しており、市場の概要、市場動向の分析、がんタイプ別・がん細胞別・診断方法別・治療別・地域別の分析、競合情勢、さらに主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と見解

  • 調査範囲
  • アナリストの見解と現在の市場動向

第3章 競合情勢

  • 主要企業分析
  • Abbvie Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • Bayer Pharma AG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • Merck & Co.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • Glaxosmithkline Plc
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • Pfizer Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析
  • 主要企業へのCOVID-19の影響

第4章 市場セグメンテーション

  • 世界の腎臓がん市場：がんタイプ別
    • 腎細胞がん（RCC）
    • 移行上皮がん
    • ウィルムス腫瘍（腎芽腫）
    • その他（肉腫、リンパ腫）
  • 世界の腎臓がん市場：がん細胞別
    • 明細胞
    • 乳頭状
    • その他
  • 世界の腎臓がん市場：診断方法別
    • 生検
    • コンピュータ断層撮影（CT）スキャン
    • 磁気共鳴画像法（MRI）
    • 超音波
  • 世界の腎臓がん市場：治療別
    • 手術
    • 免疫療法
    • 化学療法
    • 放射線治療
    • 凍結療法

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Active Biotech AB
  • Actuate Therapeutics, Inc.
  • Adaptimmune Therapeutics plc.
  • Amgen Inc.
  • Astrazeneca Plc
  • Cipla Inc.
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Novartis AG
  • Prometheus Laboratories.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL RENAL CELL CARCINOMA (RCC) KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL TRANSITIONAL CELL CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL WILM'S TUMOUR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL OTHER KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER CELL, 2021-2028 ($ MILLION)
  • 7. GLOBAL CLEAR CELL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL PAPILLARY KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL OTHER KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
  • 11. GLOBAL KIDNEY CANCER BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL KIDNEY CANCER COMPUTED TOMOGRAPHY (CT) SCAN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL KIDNEY CANCER MAGNETIC RESONANCE IMAGING (MRI) SCAN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL KIDNEY CANCER ULTRASOUND MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 16. GLOBAL KIDNEY CANCER IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL KIDNEY CANCER CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 18. GLOBAL KIDNEY CANCER RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 19. GLOBAL KIDNEY CANCER CRYOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 20. GLOBAL KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE , 2021-2028 ($ MILLION)
  • 23. NORTH AMERICAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER CELL, 2021-2028 ($ MILLION)
  • 24. NORTH AMERICAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
  • 25. NORTH AMERICAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 26. EUROPEAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 27. EUROPEAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE , 2021-2028 ($ MILLION)
  • 28. EUROPEAN KIDNEY CANCERMARKET RESEARCH AND ANALYSIS BY CANCER CELL, 2021-2028 ($ MILLION)
  • 29. EUROPEAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
  • 30. EUROPEAN KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 32. ASIA-PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER TYPE , 2021-2028 ($ MILLION)
  • 33. ASIA-PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER CELL, 2021-2028 ($ MILLION)
  • 34. ASIA-PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
  • 35. ASIA-PACIFIC KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2021-2028 ($ MILLION)
  • 36. REST OF THE WORLD KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 37. REST OF THE WORLD KIDNEY CANCERMARKET RESEARCH AND ANALYSIS BY CANCER TYPE , 2021-2028 ($ MILLION)
  • 38. REST OF THE WORLD KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY CANCER CELL, 2021-2028 ($ MILLION)
  • 39. REST OF THE WORLD KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS METHOD, 2021-2028 ($ MILLION)
  • 40. REST OF THE WORLD KIDNEY CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY0, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL KIDNEY CANCER MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL KIDNEY CANCER MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL KIDNEY CANCER MARKET, 2022-2028 (%)
  • 4. GLOBAL KIDNEY CANCER MARKET SHARE BY CANCER TYPE , 2021 VS 2028 (%)
  • 5. GLOBAL RENAL CELL CARCINOMA (RCC) KIDNEY CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL TRANSITIONAL CELL CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL WILM'S TUMOUR CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL OTHER KIDNEY CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL KIDNEY CANCER MARKET SHARE BY CANCER CELL, 2021 VS 2028 (%)
  • 10. GLOBAL CLEAR CELL KIDNEY CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL PAPILLARY KIDNEY CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL OTHER KIDNEY CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL KIDNEY CANCER MARKET SHARE BY DIAGNOSIS METHOD, 2021 VS 2028 (%)
  • 14. GLOBAL KIDNEY CANCER BIOPSY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL KIDNEY CANCER COMPUTED TOMOGRAPHY (CT) SCAN MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL KIDNEY CANCER MAGNETIC RESONANCE IMAGING (MRI) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL KIDNEY CANCER ULTRASOUND MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL KIDNEY CANCER MARKET SHARE BY THERAPY METHOD, 2021 VS 2028 (%)
  • 19. GLOBAL KIDNEY CANCER IMMUNOTHERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. GLOBAL KIDNEY CANCER CHEMOTHERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 21. GLOBAL KIDNEY CANCER RADIATION THERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 22. GLOBAL KIDNEY CANCER CRYOTHERAPY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 23. GLOBAL KIDNEY CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 24. US KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. CANADA KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. UK KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. FRANCE KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. GERMANY KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. ITALY KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. SPAIN KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. REST OF EUROPE KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 32. INDIA KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 33. CHINA KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 34. JAPAN KIDNEY CANCER MARKET SIZE, 2021-2028 ($ MILLION)
  • 35. SOUTH KOREA KIDNEY CANCERMARKET SIZE, 2021-2028 ($ MILLION)
  • 36. REST OF ASIA-PACIFIC KIDNEY CANCERMARKET SIZE, 2021-2028 ($ MILLION)
  • 37. REST OF THE WORLD KIDNEY CANCERMARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026497

Global Kidney Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, Wilm's Tumor (Nephroblastoma), and Others (Sarcoma, Lymphoma)), by Cancer Cell (Clear Cell, Papillary, and Other) by Diagnosis (Biopsy, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), and Ultrasound) and by Therapy (Surgery, Immunotherapy, Chemotherapy, Radiation Therapy, and Cryotherapy) Forecast (2022-2028)

The global kidney cancer market is anticipated to grow at a substantial CAGR of 6.2% during the forecast period. As per the American Cancer Society, kidney cancer is among the 10 most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%). Reduced physical activity and excessive smoking and drinking are also a factor that is driving the kidney cancer market.

The global kidney cancer market is segmented based on the cancer type, cancer cell, diagnosis, and therapy. Based on the cancer type, the market is segmented into renal cell carcinoma (RCC), transitional cell cancer, Wilm's tumor (nephroblastoma), and others. Based on the cancer cell, the market is sub-segmented into a clear cell, papillary, and other. Based on the diagnosis, the market is sub-segmented into biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), and ultrasound. Based on therapy, the market is sub-segmented into surgery, immunotherapy, chemotherapy, radiation therapy, and cryotherapy.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The market in the Asia-Pacific region is growing during the forecast period. The major countries contributing to the APAC region are China, Australia, Japan, and India. A large customer base, high consumption of Tabaco, and continuous increment in economy and healthcare facility are the major factor for the growth of the market in the region. The drugmaker launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer, in India. The drug is launched at an MRP that is approximately 96% lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg), and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).

The major companies serving the global kidney cancer market include AbbVie Inc., Bayer Pharma AG, Merck & Co., GlaxoSmithKline Plc, and Pfizer Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib, for the treatment of renal cell carcinoma. Cabolong is available in 20mg, 40mg, and 60mg strengths at the pricing of below ₹10,000 for a monthly treatment regimen with the highest strength.

Research Methodology

The market study of the global pharmaceutical filtration market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Kidney Cancer Market Research and Analysis by Cancer Type.

2. Global Kidney Cancer Market Research and Analysis by Cancer Cell.

3. Global Kidney Cancer Market Research and Analysis by Diagnosis.

4. Global Kidney Cancer Market Research and Analysis by Therapy.

The Report Covers:

  • Comprehensive Research Methodology of the global pharmaceutical filtration market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pharmaceutical filtration market.
  • Insights about market determinants that are stimulating the global pharmaceutical filtration market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Kidney Cancer Market
  • Recovery Scenario of Global Kidney Cancer Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Abbvie Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bayer Pharma AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Merck & Co.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Glaxosmithkline Plc
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Pfizer Inc.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis
  • 3.8. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Kidney Cancer Market by Cancer Type
    • 4.1.1. Renal Cell Carcinoma (RCC)
    • 4.1.2. Transitional Cell Cancer
    • 4.1.3. Wilm's Tumour (Nephroblastoma)
    • 4.1.4. Others (Sarcoma, Lymphoma)
  • 4.2. Global Kidney Cancer Market by Cancer Cell
    • 4.2.1. Clear Cell
    • 4.2.2. Papillary
    • 4.2.3. Other
  • 4.3. Global Kidney Cancer Market by Diagnosis Method
    • 4.3.1. Biopsy
    • 4.3.2. Computed Tomography (CT) scan
    • 4.3.3. Magnetic Resonance imaging (MRI)
    • 4.3.4. Ultrasound
  • 4.4. Global Kidney Cancer Market by Therapy
    • 4.4.1. Surgery
    • 4.4.2. Immunotherapy
    • 4.4.3. Chemotherapy
    • 4.4.4. Radiation Therapy
    • 4.4.5. Cryotherapy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profile

  • 6.1. Active Biotech AB
  • 6.2. Actuate Therapeutics, Inc.
  • 6.3. Adaptimmune Therapeutics plc.
  • 6.4. Amgen Inc.
  • 6.5. Astrazeneca Plc
  • 6.6. Cipla Inc.
  • 6.7. Eisai Co., Ltd.
  • 6.8. Exelixis, Inc.
  • 6.9. F. Hoffmann-La Roche Ltd
  • 6.10. Genentech, Inc.
  • 6.11. Jazz Pharmaceuticals, Inc.
  • 6.12. Novartis AG
  • 6.13. Prometheus Laboratories.
  • 6.14. Sanofi
  • 6.15. Takeda Pharmaceutical Co. Ltd.